Abbott settles antitrust allegations over TriCor

Abbott Laboratories stated in a regulatory filing that it intends to pay $184 million to settle class-action claims from pharmacies, wholesalers and generic-drug firms alleging that the company breached antitrust laws by working to block the launch of copies of its cholesterol drug TriCor. Abbott contends that it acted in accordance with the law and agreed to the settlement "to avoid the uncertainty of a trial outcome," a company spokeswoman said.

View Full Article in:

Wall Street Journal, The · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC